In 2025, Darnytsia Registered 6 Medicines Outside Ukraine

In 2025, Darnytsia Pharmaceutical Company registered six medicinal products in Bosnia and Herzegovina and Georgia. The company had previously been present in these markets and has now expanded its portfolio with products for the treatment of neuromuscular transmission disorders, systemic therapy and prevention of fungal infections, antibacterial therapy, as well as emergency care for headache and migraine.

“The number of high-quality Ukrainian medicines on the international market is steadily increasing. This year, we do not plan to slow down — our team is already actively working on new projects. We are preparing to introduce several more products to European as well as Middle East and North African markets*,” said Hurhen Karapetian, Export & Hospital Sales Director at Darnytsia.

“Darnytsia always adheres to the strictest global standards. Our medicines combine advanced technologies, proven effectiveness, and high safety,” adds Anna Pavliuk-Havrylova, Head of International Registration and New Market Entry at Darnytsia.

As a reminder, over the past four years, the company has registered 20 medicines outside Ukraine and entered nine new markets, including Australia, Malaysia, New Zealand, Singapore, Israel, Bosnia and Herzegovina, Poland, and the Baltic countries. Darnytsia’s products are now available in more than 20 countries worldwide.

*MENA – Middle East and North Africa